home.aspx
 
EVENTS

Symposium on Advanced Wound Care Fall
SYMPOSIUM ON ADVANCED WOUND CARE FALL
October 30-01, 2020
The Symposium on Advanced Wound Care Fall meeting (SAWC Fall) serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes thro...

Update CME - Internal Medicine & Primary Care
UPDATE CME - INTERNAL MEDICINE & PRIMARY CARE
October 29-01, 2020
Earn 30 CME Credits by attending our Update CME Internal Medicine and Primary Care Conference either in person or via live stream!Expert speakers from The University of Chicago, Johns Hopkins, and University of California, Los Angeles will be presenting on the latest clinical guidelines. We offer in...

Bioserv Corporation

SHARESHARESHARE
Bioserv Corporation located in San Diego, California is a boutique cGMP contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology, life sciences, medical device, and diagnostic industries since 1988. Bioserv’s core competency is manual filling which allows us to be very flexible and capable of handling small to medium batches effortlessly. Bioserv has a broad range of manufacturing suites to meet your production needs. Bioserv’s manufacturing facilities include certified Class 100,000 (Class 8 or Class D), Class 10,000 (Class 7 or Class C), Class 100 (Class 5 or Class A) areas, and Uncontrolled laboratory rooms. Whether a client is looking to move a drug product candidate into the pre-clinical setting, Phase I, Phase II clinic, or looking for basic reagent formulation and filling expertise, Bioserv has the experience and capabilities to get our clients there on time. We have filled a significant number of cGMP finished drug product lots for our clients to support their Phase I and Phase II clinical trial needs. We have a broad level of highly skilled production experts that have worked with very complex formulations, including liposomes, emulsions, nano-particles, small molecules, conjugates, and adjuvants.
SHARESHARESHARE

RELATED NEWS


Opioid abuse and overdose deaths saw a sharp spike in the late 1990s through today. From 1999 to 2017, almost 218,000 people died in the United States from overdoses related to prescription opioids, according to the U.S. Centers for Disease Control and Prevention (CDC). Countless lawsuits have been brought against opioid manufacturers by local governments as part of an effort to regain some compensation for the public resources spent battling opioid overdoses and addiction. It’s important ...

READ MORE

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached a tentative settlement with some of the plaintiffs last week. In the deal, Purdue would transform itself through the bankruptcy process from a typical, profit-chasing drugmaker into a “public beneficiary company.” It’s an offer that has been rejected by many of the attorneys general suing the company. They ...

READ MORE

Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents have emerged showing the US Department of Justice has launched a separate probe into its marketing. Nuplazid (pimavanserin) was first approved in April 2016 for psychosis associated with Parkinson’s disease, and although it was the first drug approved to treat the condition, marketing it has h...

READ MORE

Bayer and Loxo Oncology have agreed to work together on the development and commercialization of two novel cancer therapies, in a deal potentially worth more than $1.5 billion to the latter firm....

READ MORE

The “Cutting Edge / Drug Discovery & Development in Michigan Symposium” will feature how new therapeutic entities are being discovered and advanced from idea to clinical proof-of-concept at the University of Michigan, Wayne State University and Michigan State University, that make up the University Research Corridor (URC)....

READ MORE

After a year of negotiations, NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease drug, saying that the company is unable to address concerns about long-term effectiveness. Brineura (cerliponase alfa) is designed to treat children with Batten disease, also known as neuronal ceroid lipofuscinosis type 2 (CLN2) – a very rare inherited condition affecting between one and six babies each year in the UK. In its earlier draft guidance, published last year, NIC...

READ MORE

EVENTS

Update CME - Internal Medicine & Primary Care
UPDATE CME - INTERNAL MEDICINE & PRIMARY CARE
October 29-01, 2020
Earn 30 CME Credits by attending our Update CME Internal Medicine and Primary Care Conference either in person or via live stream!Expert speakers from The University of Chicago, Johns Hopkins, and University of California, Los Angeles will be presenting on the latest clinical guidelines. We offer in...

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...